Prostate Cancer

“If the PRECISION study results hold up in future research, any time you can avoid an invasive procedure with risks, obviously that’s good for patients,” says one urologist.

While a recent study of salvage radical prostatectomy after focal therapy demonstrates satisfactory functional outcomes, oncologic outcomes were not as good as after primary RP, said researcher Jaime O. Herrera-Caceres, MD.

Recent data support the product’s use in protecting organs at risk for radiation exposure.

"This important study provides strong validation of the utility of multiparametric MRI of the prostate prior to initial biopsy," writes Badar M. Mian, MD.

"AS is very cost effective over the short term compared to prostatectomy and radiation, but there a number of factors may impact actual AS cost savings over the long term," writes Leonard G. Gomella, MD.

Active surveillance as an initial management strategy for men with low-risk prostate cancer results in cost savings compared with immediate treatment, regardless of the treatment chosen.

To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.

The benefits of bilateral nerve-sparing procedures in men undergoing radical prostatectomy may be concentrated in those patients who have high sexual function at baseline.

Abiraterone acetate (ZYTIGA) should be considered a standard of care for newly diagnosed, metastatic, non-castrate prostate cancer, as should docetaxel (Taxotere), according to a new clinical practice guideline from ASCO.

Studies provide clear evidence to support MRI fusion biopsy’s use as the gold standard for men at risk for prostate cancer diagnosis following an initial negative biopsy.

Limitations of MRI fusion biopsy include its cost, interobserver variability, and low diagnostic accuracy for clinically significant cancer in the anterior prostate.

Evidence shows HIFU can provide cancer control outcomes comparable to those associated with radical prostatectomy or radiation therapy in properly selected patients.

Recommending either whole-gland or focal HIFU cannot be justified when their pros and cons are judged relative to the appropriate comparator.

There were significant improvements among those studied on the higher radiation dose in terms of biochemical failure and distant metastases, however.

Practicing urologists should consider the potential value of performing a multiparametric MRI for a biopsy in men with suspected prostate cancer based on results from the PRECISION trial, says Veeru Kasivisvanathan, MRCS.

A minority of patients are involved in shared decision-making about prostate cancer screening with PSA, but new strategies to incorporate shared decision-making into practice are being investigated.

"One thing I would like to see some guidance on is what to do about patients who use marijuana recreationally," says one urologist.

This article examines current developments in robotic urologic surgery and future directions, including the introduction of alternative surgical robots.

Long-term use of a multivitamin may protect against recurrence of prostate cancer, particularly in those men who have had radical prostatectomy.

Enzalutamide (XTANDI) with androgen deprivation therapy delays the development of metastatic disease in men with M0 castration-resistant prostate cancer compared with ADT alone, according to results from the randomized phase III PROSPER study.

Adding apalutamide prior to metastases may benefit men with prostate cancer who are no longer responding to androgen deprivation therapy, according to new phase III study findings.

Docetaxel (Taxotere) appears to help improve overall quality of life and delay time for subsequent therapy in men with both non-metastatic and metastatic prostate cancer, according to a new analysis of STAMPEDE trial results.

"While improving local control seems to be important, especially in those with high-risk features, it’s not clear whether adjuvant EBRT is necessarily better than early salvage EBRT," writes Badar M. Mian, MD.

Comorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).

Body mass index is an independent predictor of metastasis and prostate cancer mortality after radical prostatectomy, according to results from a large, long-term single-institution study.